Medicine and Health
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 Neo Trio trial
G. V. Long, M. S. Carlino, et al.
In a groundbreaking phase 2 trial, researchers explored the impact of combining targeted therapy with immunotherapy for patients with resectable stage III BRAFV600-mutant melanoma. Conducted by a team including Georgina V. Long and Matteo S. Carlino, the study uncovered crucial insights into treatment efficacy and recurrence rates, challenging the notion of enhanced benefits from combined therapies.
~3 min • Beginner • English
Related Publications
Explore these studies to deepen your understanding of the subject.
